Stockscreener 앱 받기
8.66
5.87%
-0.54
전일 마감가:
$9.20
열려 있는:
$9.2
하루 거래량:
211.64K
Relative Volume:
0.47
시가총액:
$1.18B
수익:
$43.34M
순이익/손실:
$-247.99M
주가수익비율:
-4.3875
EPS:
-1.9738
순현금흐름:
$-224.28M
1주 성능:
-4.63%
1개월 성능:
-14.51%
6개월 성능:
-9.32%
1년 성능:
+34.26%
1일 변동 폭
$8.575
$9.20
1주일 범위
$8.17
$9.57
52주 변동 폭
$5.05
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
8.66 | 1.18B | 43.34M | -247.99M | -224.28M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-05-28 | 개시 | Deutsche Bank | Buy |
| 2024-10-07 | 개시 | Piper Sandler | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2020-11-20 | 개시 | BofA Securities | Buy |
| 2020-09-22 | 개시 | Goldman | Buy |
| 2020-07-27 | 개시 | SVB Leerink | Outperform |
| 2020-07-24 | 개시 | Jefferies | Buy |
모두보기
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immatics NV (IMTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immatics Market Sentiment - Benzinga
Immatics NV (IMTX) Cash Flow - TradingKey
Immatics N.V. Revenue Breakdown – NASDAQ:IMTX - TradingView
IMTX|Immatics NV|Price:9.080|Chg%:-0.210 - TradingKey
Immatics NV (IMTX) Income Statement - TradingKey
Immatics N.V. (IMTX) Stock Analysis: A Deep Dive Into Its 103% Potential Upside - DirectorsTalk Interviews
Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV : Leerink Partners Assumes Covera - Moomoo
Immatics stock trades steady as pipeline and cash position frame biotech outlook - Ad-hoc-news.de
Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026 - Bitget
Immatics N.V. (IMTX) Stock: Cancer Treatment Pipeline Gains Momentum With Cell Therapy and Bispecific Programs - parameter.io
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - Investing News Network
MRNA Advances Cancer Pipeline With New Immunotherapy Study - TradingView
Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline - Quiver Quantitative
Immatics’ three ESMO presentations span melanoma and solid tumors - Stock Titan
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage R&D InvestmentEarnings Growth Analysis - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Amid Continued Pipeline ProgressPre-Announcement Alert - dars.gov.et
Immatics (IMTX) Gains Momentum, Approaches Key Resistance LevelNew Highs New Lows - dars.gov.et
(IMTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immatics (IMTX) Slides 3.11% Amid Biotech Sector Pressure – Support at $9.17 in FocusRounding Bottom - dars.gov.et
Immatics (IMTX) Holds Near Support as Slight Dip Signals Cautious TradingGap Down Bounce Plays - dars.gov.et
Immatics stock holds attention. The focus shifts to its pipeline. - Ad Hoc News
Immatics (IMTX) Q1 2026 Earnings: EPS Miss Weighs on Pre-Revenue Biotech StockRevenue Beat Analysis - Bölüm Sonu Canavarı
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Development Costs WeighQuarterly Earnings - dars.gov.et
Immatics N.V. Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage InvestmentEarnings Sentiment Score - dars.gov.et
Responsive Playbooks and the IMTX Inflection - Stock Traders Daily
Immatics N.V. Actuals & Estimates (NASDAQ:IMTX) - TradingView
Immatics (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentRevenue Guidance Range - dars.gov.et
Enterprise value to revenue forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Price to book forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Enterprise value to EBIT forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Enterprise value to EBIT forward of Immatics N.V. – MUN:4A3 - TradingView
IMTX Forecast — Price Target — Prediction for 2027 - TradingView
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Higher R&D Investment; Pipeline Progress Continues - dars.gov.et
Immatics N.V. Actuals & Estimates (TRADEGATE:4A3) - TradingView
Immatics N.V. Actuals & Estimates (FWB:4A3) - TradingView
Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV (IMTX) Institutional Confidence - TradingKey
Understanding the Setup: (IMTX) and Scalable Risk - Stock Traders Daily
Immatics Shareholders Approve All Proposals at June 18, 2026 AGM - The Globe and Mail
Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award - Stock Titan
Immatics (IMTX) awards director Alise Reicin 48,000 stock options - Stock Titan
Immatics (IMTX) director receives grant of 48,000 stock options at $9.09 - Stock Titan
Immatics (IMTX) director receives 48,000 stock options vesting in 2026 - Stock Titan
Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares - Stock Titan
Immatics N.V. (IMTX) director awarded 48,000 stock options at $9.09 - Stock Titan
Immatics (IMTX) director Heather Mason receives 48,000 stock options at $9.09 strike - Stock Titan
48,000 Immatics (IMTX) options tied to board role granted - Stock Titan
Immatics N V (IMTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):